Clinical Trial Update: Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of once-weekly KAI-9531 versus semaglutide and placebo in adults with obesity who do not have diabetes; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• KAI-9531
• semaglutide (semaglutide)

Snippet

Sponsor: Kailera | Conditions: Obesity | Phase 3 | Status: RECRUITING